Natera generated $696.6 million in revenues for the quarter ended March 31, 2026, up 38.8% from $501.8 million a year earlier. This robust growth was fueled by increased adoption of its cell-free DNA and genetic testing services across prenatal, oncology and transplant markets.

The company achieved a gross margin of 64.7% in Q1 2026, an improvement from 63.1% in Q1 2025. Margin expansion reflects scale efficiencies, cost optimization in laboratory operations and favorable product mix as higher-value tests gained traction.